Dissecting the immune response to MF59-adjuvanted and nonadjuvanted seasonal influenza vaccines in children less than three years of age

Pediatric Infectious Disease Journal

Volumn 34, Issue 1, 2015, Pages 73-78

  Zedda, Luisanna ^a,b   Forleo Neto, Eduardo ^a,b   Vertruyen, André ^c   Raes, Marc ^d   Marchant, Arnaud ^e,f   Jansen, Wim ^a,b   Clouting, Heather ^a,b   Arora, Ashwani ^a,b   Beatty, Mark E ^a,b   Galli, Grazia ^a,b   Del Giudice, Giuseppe ^a,b   Castellino, Flora ^a,b  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b Sint Vincentius Ziekenhuis ^*  (United States)

^c Sint Vincentiusziekenhuis   (Belgium)

^d Kinderartsenassociatie   (Belgium)

^e ImmuneHealth   (Belgium)

^f UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

CD4+ T cells; Infant; Influenza; MF59; Vaccination

Indexed keywords

GAMMA INTERFERON; HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; INTERLEUKIN 13; INTERLEUKIN 2; MIFAMURTIDE; TUMOR NECROSIS FACTOR ALPHA; IMMUNOLOGICAL ADJUVANT; MF59 OIL EMULSION; POLYSORBATE; SQUALENE; TUMOR NECROSIS FACTOR; VIRUS ANTIBODY;

ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; CHILDHOOD DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFLUENZA VACCINATION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEASONAL INFLUENZA; TH1 CELL; TH2 CELL; TREATMENT DURATION; BLOOD; CLINICAL TRIAL; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; PRESCHOOL CHILD; SECRETION (PROCESS); TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CHILD, PRESCHOOL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFANT; INFLUENZA VACCINES; INTERLEUKIN-2; MALE; POLYSORBATES; SQUALENE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84926168011     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000465     Document Type: Article

References (20)

1. Loeb M, Singh PK, Fox J, et al. Longitudinal study of influenza molecular viral shedding in Hutterite communities. J Infect Dis. 2012;206:1078-1084.
2. Control Centers for Disease, and Prevention. Prevention and control of seasonal influenza with vaccines. Recommendations of the advisory committee on immunization practices-United States, 2013-2014. MMWR Recomm Rep. 2013;62:1-43.
3. Neuzil KM, Englund JA. Influenza vaccine for young children: two doses are better than one. J Pediatr. 2006;149:737-738.
4. Vesikari T, Knuf M, Wutzler P, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med. 2011;365:1406-1416.
5. O'Hagan DT, Ott GS, Van Nest G, et al. The history of MF59 adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines. 2013;12:13-30.
6. Pellegrini M, Nicolay U, Lindert K, et al. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine. 2009;27:6959-6965.
7. Black S, Della Cioppa G, Malfroot A, et al. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Vaccine. 2010;28:7331-7336.
8. Mannino S, Villa M, Apolone G, et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol. 2012;176:527-533.
9. Van Buynder PG, Konrad S, Van Buynder JL, et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine. 2013;31:6122-6128.
10. Vesikari T, Pellegrini M, Karvonen A, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J. 2009;28:563-571.
11. Galli G, Medini D, Borgogni E, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A. 2009;106:3877-3882.
12. Spensieri F., Borgogni E., Zedda L., et al. Human circulating influenza-CD4+ICOS1+IL-2+ T cells expand after vaccination, exert helper function, and predict antibody responses. Proc Natl Acad Sci U S A. 2013;110:14330-14335.
13. Black S, Nicolay U, Vesikari T, et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J. 2011;30:1081-1085.
14. Vesikari T, Groth N, Karvonen A, et al. MF59-adjuvanted influenza vaccine (Fluad) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine. 2009;27:6291-6295.
15. Della Cioppa G, Nicolay U, Lindert K, et al. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 adjuvant: results from a dose-finding clinical trial in older adults. Hum Vaccin Immunother. 2012;8:216-227.
16. Della Cioppa G, Vesikari T, Sokal E, et al. Trivalent and quadrivalent MF59-adjuvanted influenza vaccine in young children: a dose- and schedulefinding study. Vaccine. 2011;29:8696-8704.
17. Galli G, Hancock K, Hoschler K, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A. 2009;106:7962-7967.
18. Chotpitayasunondh T, Thisyakorn U, Pancharoen C, et al. Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A/H5N1 vaccine in children. PLoS One. 2008;3:e4028.
19. Diez-Domingo J, Garces-Sanchez M, Baldo JM, et al. Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase II, randomized, open, controlled study. Pediatr Infect Dis J. 2010;29:e35-e46.
20. Amato-Gauci A, Zucs P, Snacken R, et al. Surveillance trends of the 2009 influenza a (H1n1) pandemic in Europe. Euro Surveill. 2011;16:pii:19903.